Table 7.
Clinical trials of immune checkpoint stimulators in lymphoma.
| Trial ID (Name) | Authors | Year | Intervention(s) | Target(s) | Phase | Disease(s) | N | CR | OR | PFS |
|---|---|---|---|---|---|---|---|---|---|---|
|
NCT01471210 (CA186-011) |
Segal et al. | 2017 | Urelumab | CD137 (4-1BB) | I | B-NHL | 11 | N.A. | N.A. | N.A. |
| NCT01307267 | Segal et al. | 2018 | Utomilumab | CD137 (4-1BB) | I | Lymphoma a | 2 | N.A. | N.A. | N.A. |
| NCT01307267 | Gopal et al. | 2020 | Utomilumab + Rituximab | CD137 (4-1BB) | I | FL DLBCL MCL CLL/SLL MZL NLPHL |
47 7 6 3 2 1 |
9% 0% 0% 0% 0% 0% |
23% 14% 17% 0% 0% 100% |
median 4.6 months b |
|
NCT01471210 (CA186-011) |
Timmerman et al. | 2020 | Urelumab | CD137 (4-1BB) | I | DLBCL FL other B-NHL |
31 29 12 |
0% 6% 17% |
6% 12% 17% |
median 8.1 weeks median 8.9 weeks median 13.4 weeks |
|
NCT01775631 (CA186-017) |
Timmerman et al. | 2020 | Urelumab + Rituximab | CD137 (4-1BB) | Ib | DLBCL FL |
29 17 |
7% 12% |
10% 35% |
median 9.0 weeks median 40.4 weeks |
| NCT01470134 | Ansell et al. | 2020 | Varlilumab | CD27 | I | DLBCL FL other B-NHL cHL PTCL CTCL MF |
10 6 2 11 2 1 2 |
0% 0% 0% 9% 0% 0% 0% |
0% 0% 0% 9% 0% 0% 0% |
N.A. |
| NCT00103779 | Advani et al. | 2009 | Dacetuzumab | CD40 | I | DLBCL FL MCL MZL CLL/SLL other NHL |
21 12 10 3 1 3 |
5% 0% 0% 0% 0% 0% |
10% 0% 10% 33% 0% 0% |
N.A. |
| NCT00283101 | Furman et al. | 2010 | Dacetuzumab | CD40 | I | CLL | 12 | 0% | 0% | N.A. |
| NCT00108108 | Byrd et al. | 2012 | Lucatumumab | CD40 | I | CLL | 24 | 0% | 4% | N.A. |
| NCT00655837 | Forero-Torres et al. | 2013 | Dacetuzumab + Rituximab + Gemcitabine | CD40 | Ib | DLBCL | 30 | 20% | 47% | median 25 weeks |
| NCT00435916 | de Vos et al. | 2014 | Dacetuzumab | CD40 | II | DLBCL FL MZL |
40 3 2 |
5% 0% 0% |
8% 33% 0% |
median 36 days |
| NCT00670592 | Fanale et al. | 2014 | Lucatumumab | CD40 | Ia/II | FL DLBCL MALT MCL cHL |
21 34 7 12 37 |
5% 6% 14% 0% 0% |
33% 12% 43% 0% 14% |
N.A. |
| NCT00529503 | Fayad et al. | 2015 | Dacetuzumab + R-ICE Placebo + R-ICE |
CD40 | IIb | DLBCL | 75 76 |
33% 36% |
67% 64% |
median 12.1 months median 6.5 months |
All disease groups are relapsed/refractory unless otherwise specified. a Subtype not specified. b For patients with NHL. Abbreviations: N, number of patients; CR, complete response, OR, overall response; PFS, progression free survival; N.A., not assessed.